ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement

Wednesday, June 17, 2015

Submitted by

J. Rafael Sadaba

Source

Source Name: Journal of the American College of Cardiology

Source URL: http://content.onlinejacc.org/article.aspx?articleid=2319410

Author(s)

Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, Heiser J, Merhi W, Zorn GL 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Maini B, Mumtaz M, Conte JV, Resar JR, Aharonian V, Pfeffer T, Oh JK, Qiao H, Popma JJ.

In this paper the authors report on the 2-year results of the randomized US pivotal trial for surgical and self-expanding percutaneous aortic prosthetic valves. The survival benefit observed at 1 year in the transcatheter group were sustained at two years. This was also the case for the significant reduction in major adverse clinical and cerebrovascular events. These results lead the authors to suggest that self-expanding transcatheter valve therapy should be considered the standard of care and preferred over surgery in the study population.